A study report presented at American Association for Cancer Research's Frontiers in Cancer Prevention Research meeting in Boston has evaluated a vaccine that is showing positive results for women, who are at high risk of breast cancer

Study Findings
a. A vaccine targeting HER-2/neu over-expression, in early stage breast cancer, known as DCIS (early stage cancer formation in the breast's milk ducts). Researchers have estimated that in about 50-60% of women DCIS is directly related to HER-2/neu over-expression.
b. Study found that majority of the patients responded well to the vaccination. Almost, all patients (11 of 12) exhibited an initial immune response (shown by the presence of anti-HER-2/neu specific CD4+ T cells), and many of the patients developed protein antibodies to
fight the HER-2/neu cells.
c. In many of the patients, the number of white blood cells have increased, following the treatment, thus showing long-term immune responses to HER-2/neu.
d. Out of 12 study participants, 6 showed reduced levels of HER-2/neu expression after the vaccination. Investigators also noted an improvement in their severity of their disease.

Researchers feel that results demonstrated by the DC vaccination may have significant clinical activity against certain types of breast cancer.